7.75
0.11 (1.44%)
| Previous Close | 7.64 |
| Open | 7.55 |
| Volume | 726,874 |
| Avg. Volume (3M) | 799,941 |
| Market Cap | 611,895,616 |
| Price / Earnings (TTM) | 71.55 |
| Price / Earnings (Forward) | 66.23 |
| Price / Sales | 6.23 |
| Price / Book | 13.39 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | 8.59% |
| Operating Margin (TTM) | 24.42% |
| Diluted EPS (TTM) | 0.110 |
| Quarterly Revenue Growth (YOY) | 37.40% |
| Quarterly Earnings Growth (YOY) | 6,197.40% |
| Total Debt/Equity (MRQ) | 5.75% |
| Current Ratio (MRQ) | 3.57 |
| Operating Cash Flow (TTM) | 12.11 M |
| Levered Free Cash Flow (TTM) | 9.61 M |
| Return on Assets (TTM) | 7.84% |
| Return on Equity (TTM) | 22.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Packaged Foods (US) | Mixed | Bearish |
| Packaged Foods (Global) | Mixed | Mixed | |
| Stock | ChromaDex Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.5 |
| Average | 1.25 |
|
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment. |
|
| Sector | Consumer Defensive |
| Industry | Packaged Foods |
| Investment Style | Small Core |
| % Held by Insiders | 34.79% |
| % Held by Institutions | 30.00% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (HC Wainwright & Co., 41.94%) | Buy |
| Median | 9.55 (23.23%) | |
| Low | 8.10 (Ladenburg Thalmann, 4.52%) | Buy |
| Average | 9.55 (23.23%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.25 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Mar 2025 | 11.00 (41.94%) | Buy | 7.94 |
| 10 Mar 2025 | 11.00 (41.94%) | Buy | 7.88 | |
| Ladenburg Thalmann | 05 Mar 2025 | 8.10 (4.52%) | Buy | 8.55 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |